{"id":1890,"date":"2026-07-09T22:18:39","date_gmt":"2026-07-10T02:18:39","guid":{"rendered":"https:\/\/www.insilens.com\/?p=1890"},"modified":"2026-07-09T22:20:54","modified_gmt":"2026-07-10T02:20:54","slug":"fate-ft839-dual-cd19-cd38-car-t-cleared","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=1890","title":{"rendered":"Fate FT839 Dual CD19\/CD38 CAR-T Cleared"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Company<\/strong><\/p>

Fate Therapeutics, Inc. (Nasdaq: FATE)<\/p>

Event Type<\/strong><\/p>

FDA clearance of Investigational New Drug (IND) application<\/p>

Modality<\/strong><\/p>

Off-the-shelf, iPSC-derived allogeneic dual-CAR T cell \u2014 13-point genetically edited, manufactured from a renewable master cell bank<\/p>

Targets<\/strong><\/p>

CD19 and CD38 \u2014 dual antigen co-targeting<\/p>

Indication<\/strong><\/p>

Phase 1\/2 basket trial across B cell-mediated autoimmune diseases; mechanism explicitly extends to B-cell lymphomas, leukemias, and multiple myeloma<\/p>

Summary<\/strong><\/p>

Fate Therapeutics announced that the FDA has cleared its IND application for FT839, a next-generation, off-the-shelf CAR T-cell therapy co-targeting CD19 and CD38. The company plans to initiate a Phase 1\/2 basket trial across multiple B cell-mediated autoimmune diseases, with patient enrollment expected in the second half of 2026.<\/p>

FT839 is engineered from Fate’s clonal induced pluripotent stem cell (iPSC) master cell bank and incorporates thirteen distinct genetic edits designed to enhance T-cell persistence, evade host allogeneic rejection, improve safety, and ensure batch-to-batch manufacturing consistency. Critically, the company states that FT839’s dual CD19\/CD38 targeting mechanism supports potential application in B-cell lymphomas, leukemias, and multiple myeloma.<\/p>

\u00a0<\/p>

Why It Matters<\/strong><\/p>

FT839 sits precisely at the intersection of the highest-value trends in cell therapy: off-the-shelf allogeneic manufacturing, iPSC-derived renewable sourcing, and dual-antigen co-targeting. The choice of CD19 and CD38 is strategically significant. CD19 is the canonical B-cell lineage antigen validated across lymphoma and leukemia; CD38 is the defining plasma-cell antigen central to multiple myeloma and the target of the daratumumab and isatuximab franchises. Co-targeting both antigens in a single product spans the entire B-lineage maturation axis from mature B cells to terminally differentiated plasma cells \u2014 addressing antigen escape, a principal mechanism of relapse following single-target CAR-T therapy.<\/p>

Competitive Displacement<\/strong><\/p>

  • Autologous CAR-T manufacturing models \u2014 an off-the-shelf, conditioning-optimized product challenges the cost, vein-to-vein time, and manufacturing complexity of patient-specific CAR-T<\/li>
  • Donor-derived allogeneic CAR-T programs \u2014 iPSC-derived sourcing offers renewable, clonal, batch-consistent manufacturing versus finite healthy-donor apheresis<\/li>
  • CD19-directed B-cell depletion antibodies \u2014 a durable single-infusion cell therapy competes with chronic antibody dosing regimens<\/li>
  • CD38 antibody franchises in plasma-cell disease \u2014 dual CD19\/CD38 CAR-T could eventually contest the daratumumab and isatuximab position in myeloma<\/li><\/ul>

    Signal Strength Rationale<\/strong><\/p>

    Rated Signal 4 \u2014 Major Milestone. FDA IND clearance of a platform-defining, dual-target, off-the-shelf CAR-T with explicit hematologic malignancy potential is a substantive regulatory and platform milestone. Rating is not Signal 5 because the cleared trial is in autoimmune disease and no hematologic malignancy clinical data yet exists for FT839. Upgrade trigger: IND expansion or first clinical data in a hematologic malignancy indication.<\/p>

    Forward Catalyst<\/strong><\/p>

    Phase 1\/2 basket trial enrollment \u2014 second half of 2026. First safety and biomarker data would represent the next major inflection point for the FT839 program and Fate’s iPSC dual-CAR platform.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Company Fate Therapeutics, Inc. (Nasdaq: FATE) Event Type FDA clearance of Investigational New Drug (IND) application Modality Off-the-shelf, iPSC-derived allogeneic dual-CAR T cell \u2014 13-point genetically edited, manufactured from a renewable master cell bank Targets CD19 and CD38 \u2014 dual antigen co-targeting Indication Phase 1\/2 basket trial across B cell-mediated autoimmune diseases; mechanism explicitly extends […]<\/p>\n","protected":false},"author":1,"featured_media":1891,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,3],"tags":[],"class_list":["post-1890","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-therapeutic-indication"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1890"}],"version-history":[{"count":4,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1890\/revisions"}],"predecessor-version":[{"id":1895,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1890\/revisions\/1895"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/1891"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}